
Opinion|Videos|July 29, 2024
Leveraging MAICs for Decision-Making in CLL BTK Inhibitor Selection
Experts discuss leveraging MAICs for decision-making when choosing a CLL BTK inhibitor.
Advertisement
Episodes in this series

Video content above is prompted by the following question(s):
- How do you choose between BTK inhibitors in patients with relapsed/refractory (R/R) CLL?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Mirvetuximab Soravtansine Demonstrates Promising Efficacy, Safety in Platinum-Resistant Recurrent Ovarian Cancer
2
How Artificial Intelligence Is Transforming Leukemia Detection and Diagnosis
3
Zanubrutinib Shows Similar Efficacy but Better Safety Than VEN–I in Frontline CLL
4
FDA Approves Sibeprenlimab for Immunoglobulin A Nephropathy
5













































